Media

May 5, 2023

Convergent raises $90M to develop its radiopharmaceutical for prostate cancer

BioPharma Dive

May 3, 2023

May 3 Quick Takes: Clinical-stage targeted radio-antibody newco Convergent raises $90M A round

BioCentury

May 3, 2023

Six-person Cornell spinout raises $90M for prostate cancer drugs

The Boston Business Journal

May 3, 2023

Cambridge biotech raises $90 million for drug that uses radioactive atoms to fight prostate cancer

The Boston Globe

May 3, 2023

Radiopharmaceutical company Convergent closes series A to the tune of $90M

Fierce Biotech

May 3, 2023

Radioantibody startup led by prostate cancer experts raises $90M

Endpoints News

March 3, 2023

Dr. Bander on Preliminary Data on 225Ac-J591 Plus Pembrolizumab in mCRPC

OncLive

January 26, 2022

Dr. Philip Kantoff — Radiopharmaceutical cancer targeting with Convergent Therapeutics

Founders Keepers

January 10, 2023

Convergent Therapeutics, Inc. Next Generation Radiopharmaceutical Therapies for Prostate – Philip Kantoff

URO Today

October 16, 2022

The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer – Philip Kantoff

URO Today

October, 2022

ESMO 2022: Advances in the Treatment of Cancer

The Onco’Zine Brief

October, 2022

Developing Next-Generation Radiopharmaceuticals

The Bio Report

August 11, 2022

Radioligands Advance Radiotherapy Premise With Greater Precision

In Vivo Pharma Intelligence – Informa

August 7, 2022

Philip Kantoff: Next Generation Radiopharmaceutical Drug Development

Hopkins Biotech Podcast

July 21, 2022

Convergent Therapeutics Banking on Radioantibody Approach for PSMA-Targeted mCRPC Treatment

Precision Oncology News

July 6, 2022

Interview with Convergent Therapeutics CEO Dr. Phil Kantoff

HealthBiz Podcast with David E. Williams

June 24, 2022

Convergent Therapeutics — Next Generation Radiopharmaceutical Therapies for Cancer

Health Professional Radio

June 13, 2022

The Coming Wave Of Radio(bio)pharmaceuticals

BioProcess Online

May 30, 2022

Radiopharmaceutical Technology Creates Novel Radioantibodies to Treat Prostate Cancer with Dr. Phil Kantoff and Alex Brown — Convergent Therapeutics

Empowered Patient Podcast

April 14, 2022

AACR: Philip Kantoff Discusses Convergent's Unique Path to Treating Prostate Cancer

BioSpace

Media

Convergent raises $90M to develop its radiopharmaceutical for prostate cancer

May 3 Quick Takes: Clinical-stage targeted radio-antibody newco Convergent raises $90M A round

Six-person Cornell spinout raises $90M for prostate cancer drugs

Cambridge biotech raises $90 million for drug that uses radioactive atoms to fight prostate cancer

Radiopharmaceutical company Convergent closes series A to the tune of $90M

Radioantibody startup led by prostate cancer experts raises $90M

Dr. Bander on Preliminary Data on 225Ac-J591 Plus Pembrolizumab in mCRPC

Dr. Philip Kantoff — Radiopharmaceutical cancer targeting with Convergent Therapeutics

Convergent Therapeutics, Inc. Next Generation Radiopharmaceutical Therapies for Prostate – Philip Kantoff

The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer – Philip Kantoff

ESMO 2022: Advances in the Treatment of Cancer

Developing Next-Generation Radiopharmaceuticals

Radioligands Advance Radiotherapy Premise With Greater Precision

Philip Kantoff: Next Generation Radiopharmaceutical Drug Development

Convergent Therapeutics Banking on Radioantibody Approach for PSMA-Targeted mCRPC Treatment

Interview with Convergent Therapeutics CEO Dr. Phil Kantoff

Convergent Therapeutics — Next Generation Radiopharmaceutical Therapies for Cancer

The Coming Wave Of Radio(bio)pharmaceuticals

Radiopharmaceutical Technology Creates Novel Radioantibodies to Treat Prostate Cancer with Dr. Phil Kantoff and Alex Brown — Convergent Therapeutics

AACR: Philip Kantoff Discusses Convergent's Unique Path to Treating Prostate Cancer

Company

Connect

Contact